High Parasitological Failure Rate of Visceral Leishmaniasis to Sodium Stibogluconate among HIV Co-infected Adults in Ethiopia

PLoS Neglected Tropical Diseases

Volumn 8, Issue 5, 2014, Pages

  Diro, Ermias ^a,b   Lynen, Lutgarde ^b   Mohammed, Rezika ^a   Boelaert, Marleen ^b   Hailu, Asrat ^c   van Griensven, Johan ^b  

^a UNIVERSITY OF GONDAR   (Ethiopia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c ADDIS ABABA UNIVERSITY   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; AMYLASE; CREATININE; EFAVIRENZ PLUS LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; MILTEFOSINE; PAROMOMYCIN; PROTEINASE INHIBITOR; STIBOGLUCONATE SODIUM; ANTIMONY GLUCONATE; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CARDIOTOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG MONITORING; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PANCREATITIS; PARASITE LOAD; RECURRENCE RISK; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; ETHIOPIA; HIV INFECTIONS; LEISHMANIASIS, VISCERAL; PARASITOLOGY; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; COINFECTION; ETHIOPIA; FEMALE; HIV INFECTIONS; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PARASITE LOAD; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84901792311     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002875     Document Type: Article

References (29)

1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, et al. (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7: e35671 10.1371/journal.pone.0035671 [doi];PONE-D-11-24894 [pii].
2. Hotez PJ, Fenwick A, Savioli L, Molyneux DH, (2009) Rescuing the bottom billion through control of neglected tropical diseases. Lancet 373: 1570-1575 S0140-6736(09)60233-6 [pii];10.1016/S0140-6736(09)60233-6 [doi].
3. Hotez PJ, Kamath A, (2009) Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden. PLoS Negl Trop Dis 3: e412 10.1371/journal.pntd.0000412 [doi].
4. Liese B, Rosenberg M, Schratz A, (2010) Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. Lancet 375: 67-76 S0140-6736(09)61749-9 [pii];10.1016/S0140-6736(09)61749-9 [doi].
5. van Griensven J, Diro E, (2012) Visceral leishmaniasis. Infect Dis Clin North Am 26: 309-322 S0891-5520(12)00014-1 [pii];10.1016/j.idc.2012.03.005 [doi].
6. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, et al. (1997) Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10: 298-319.
7. Gundel Harms, Hermann Feldmeier, (2013) Review: HIV infection and tropical parasitic diseases - deleterious interactions in both directions? Trop Med Int Health 7: 479-488.
8. Mengistu G, Ayele B (2007) Visceral Leishmaniasis and HIV co-infection in patients admitted to Gondar university hospital, northwest Ethiopia. Ethiopian Journal of Health Development 53-60.
9. Cota GF, de Sousa MR, Rabello A, (2011) Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS Negl Trop Dis 5: e1153 10.1371/journal.pntd.0001153 [doi];PNTD-D-10-00249 [pii].
10. Fenske S, Stellbrink HJ, Albrecht H, Greten H, (1991) Visceral leishmaniasis in an HIV-infected patient: clinical features and response to treatment. Klin Wochenschr 69: 793-796.
11. Hurissa Z, Gebre-Silassie S, Hailu W, Tefera T, Lalloo DG, et al. (2010) Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia. Trop Med Int Health 15: 848-855 TMI2550 [pii];10.1111/j.1365-3156.2010.02550.x [doi].
12. Petter A, Shetty-Lee A, Kofler G, Huemer HP, Larcher C, (2001) Visceral leishmaniasis in an AIDS patient on successful antiretroviral therapy: failure of parasite eradication despite increase in CD4+ T-cell count but low CD8+ T-cell count. Scand J Infect Dis 33: 236-238.
13. Control of the Leishmaniases. WHO Technical Report Series 949: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-226 March 2010.
14. Hailu W, Weldegebreal T, Hurissa Z, Tafes H, Omollo R, et al. (2010) Safety and effectiveness of meglumine antimoniate in the treatment of Ethiopian visceral leishmaniasis patients with and without HIV co-infection. Trans R Soc Trop Med Hyg 104: 706-712 S0035-9203(10)00167-7 [pii];10.1016/j.trstmh.2010.07.007 [doi].
15. Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, et al. (2012) Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis 6: e1674 10.1371/journal.pntd.0001674 [doi];PNTD-D-11-01022 [pii].
16. Ritmeijer K, Veeken H, Melaku Y, Leal G, Amsalu R, et al. (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 95: 668-672.
17. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, et al. (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43: 357-364 CID39077 [pii];10.1086/505217 [doi].
18. Sundar S, Chakravarty J, (2010) Antimony toxicity. Int J Environ Res Public Health 7: 4267-4277 10.3390/ijerph7124267 [doi].
19. Federal Ministry of Health, Ethiopia (2013) Guidelines for diagnosis, treatment and prevention of leishmaniasis in Ethiopia, 2nd edition.
20. Balasegaram M, Ritmeijer K, Lima MA, Burza S, Ortiz GG, et al. (2012) Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 17: 493-510 10.1517/14728214.2012.748036 [doi].
21. den Boer M, Argaw D, Jannin J, Alvar J, (2011) Leishmaniasis impact and treatment access. Clin Microbiol Infect 17: 1471-1477 10.1111/j.1469-0691.2011.03635.x [doi].
22. Chakravarty J, Sundar S, (2010) Drug resistance in leishmaniasis. J Glob Infect Dis 2: 167-176 10.4103/0974-777X.62887 [doi].
23. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN, (2008) Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 46: 1702-1709 10.1086/587899 [doi].
24. Cortes E, Ribera E, Cucurull E, de OJ, Ocana I, et al. (1995) [Acute pancreatitis due to antimonials in patients with visceral leishmaniasis and HIV infection]. Med Clin (Barc) 104: 578-580.
25. Delgado J, Macias J, Pineda JA, Corzo JE, Gonzalez-Moreno MP, et al. (1999) High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am J Trop Med Hyg 61: 766-769.
26. Federal HIV/AIDS prevention and control office and Federal Minsitry of Health (2007) Guidelines for management of opportunistic infections and antiretroviral treatment in adolescents and adults in Ethiopia.
27. In Trials of Adult Pancreatic Islet Transplantation (8-3-2011) Terminology Criteria for Adverse Events (TCAE).
28. Cota GF, de Sousa MR, Fereguetti TO, Rabello A, (2013) Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison. PLoS Negl Trop Dis 7: e2195 10.1371/journal.pntd.0002195 [doi];PNTD-D-12-01655 [pii].
29. Khalil EA, El Hassan AM, Zijlstra EE, Hashim FA, Ibrahim ME, et al. (1998) Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol 92: 151-158.